8-K: Armata Pharmaceuticals Secures $4.65 Million in Additional DoD Funding for Bacteriophage Therapy Development

Armata Pharmaceuticals receives $4.65 million in additional non-dilutive funding from the Department of Defense to advance its AP-SA02 clinical trial for Staphylococcus aureus bacteremia.

Summary

• Armata Pharmaceuticals has been awarded an additional $4.65 million in non-dilutive funding from the U.S. Department of Defense (DoD).
• This funding supports the clinical development of AP-SA02, a bacteriophage therapy for complicated Staphylococcus aureus bacteremia (SAB).
• The total award from the DoD now stands at $26.2 million.
• The new funds will be used for Phase 2a study close-out activities and preparation for an end-of-phase 2 meeting with the FDA.
• Topline data from the Phase 1b/2a diSArm trial is expected in Q2 2025.
• The diSArm study enrolled 50 subjects and evaluated the safety, tolerability, and efficacy of AP-SA02 as an adjunct to best available antibiotic therapy.
• The company observed a subset of subjects with evidence of in vivo phage amplification, suggesting the phages targeted and killed active SAB reservoirs.
• Armata filed its Annual Report for the year ended December 31, 2024, on Form 10-K with the SEC on March 21, 2025, which included a going concern explanatory paragraph.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the additional funding and progress in clinical trials, but tempered by the going concern note in the annual report.

Positives

• The additional funding strengthens Armata's financial position and supports the continued development of AP-SA02.
• The non-dilutive nature of the funding is favorable for existing shareholders.
• The observed in vivo phage amplification in a subset of patients is a promising sign for the efficacy of AP-SA02.
• The company's in-house manufacturing capacity ensures control over production and potential for immediate access to patients if AP-SA02 is approved.
• The DoD's continued support highlights the importance of AP-SA02 in addressing antibiotic-resistant infections.

Negatives

• The company's Annual Report for the year ended December 31, 2024, included a going concern explanatory paragraph, indicating potential financial challenges.
• The announcement is made pursuant to the disclosure requirements of NYSE American Company Guide Sections 401(h) and 610(b) and does not represent any change or amendment to the Company's financial statements or to its Annual Report on Form 10-K for the year ended December 31, 2024.

Risks

• The development of bacteriophage-based therapies is subject to inherent risks and uncertainties.
• The company's ability to meet anticipated milestones in the development and testing of AP-SA02 is not guaranteed.
• Regulatory approval of AP-SA02 is not assured, and commercialization may not be successful.
• The company's estimates regarding anticipated operating losses and capital requirements may be inaccurate.
• The company's ability to staff and maintain its production facilities under fully compliant current Good Manufacturing Practices is not guaranteed.

Future Outlook

Armata anticipates receiving topline data from the diSArm study in Q2 2025, which will inform the optimal dose of AP-SA02 for a larger efficacy study. The company remains focused on advancing AP-SA02 through clinical development and introducing it as a novel phage-based anti-infective.

Management Comments

• Dr. Deborah Birx, CEO of Armata, stated that the DoD has been an essential partner and expressed gratitude for their continued support.
• Dr. Birx emphasized Armata's commitment to efficiently advance AP-SA02 and introduce it for the benefit of military personnel and civilians.
• Dr. Birx concluded that Armata is laser-focused on demonstrating the potential of phage therapy and has developed proprietary manufacturing processes to support clinical development and future commercial production.

Industry Context

The announcement highlights the growing interest in bacteriophage therapy as a potential solution to combat antibiotic-resistant infections. With the rise of superbugs, alternative approaches like phage therapy are gaining traction and attracting funding from government agencies like the DoD.

Comparison to Industry Standards

• Companies like Adaptive Phage Therapeutics are also developing phage-based therapies, but Armata's focus on Staphylococcus aureus bacteremia and its in-house manufacturing capabilities differentiate it.
• The $26.2 million DoD award is significant compared to other grants in the phage therapy space, indicating strong government support for Armata's approach.
• The Phase 1b/2a diSArm trial is comparable to other early-stage clinical trials for phage therapies, but the observed in vivo phage amplification could be a differentiating factor.

Stakeholder Impact

• Shareholders will benefit from the non-dilutive funding and potential for AP-SA02 to address a significant unmet medical need.
• Employees will have the opportunity to contribute to the development of a novel therapy.
• Patients with Staphylococcus aureus bacteremia may benefit from a new treatment option.
• The DoD will have access to a potential solution for antibiotic-resistant infections in military personnel.

Next Steps

• Armata will use the additional funding to support Phase 2a study close-out activities.
• The company will prepare for an end-of-phase 2 meeting with the FDA.
• Armata anticipates receiving topline data from the diSArm study in Q2 2025.
• The company will explore the two subsets of subjects in an unblinded manner.
• Topline results are expected to inform the optimal dose of AP-SA02 for a larger efficacy study.

Key Dates

Keywords

Armata Pharmaceuticals, bacteriophage therapy, AP-SA02, Staphylococcus aureus bacteremia, DoD funding, clinical trial, antibiotic-resistant infections, MTEC, NMRC, NAMD